ECARX Pays US$10M to Kill US$100M Convertible Note Overhang
ECX is trading near its 52-week low of $0.786 (12% above the low).
Summary
ECARX paid a US$10 million cash fee to terminate an investor's right to purchase up to US$100 million of additional convertible notes, cutting potential future dilution at the cost of near-term cash.
Key Events · Financing and Capital Events · ECX
-
US$100M Note Optionality Terminated
Investor irrevocably waived its right to purchase up to US$100 million of additional convertible notes under the October 30, 2025 securities purchase agreement; no further notes will be issued under that agreement.
-
US$10M Cash Fee Payable
ECARX agreed to pay the investor a one-time US$10 million cash fee on or before October 26, 2026 — real cash out the door, not a non-cash charge.
-
Dilution Risk Removed
The cancelled notes could have been amortized at prices linked to ECARX's prevailing share price; with the stock at $0.88, that structure carried substantial share-issuance risk that is now eliminated.
-
Remaining Convertible Program Intact
The 2025 convertible notes program, upsized to a maximum of US$130 million in July 2026, carries an initial conversion price of US$2.62 and matures in 2028; the initial US$50 million note issued in October 2025 remains outstanding.
Analysis · ECX · Technology
ECARX is buying back dilution risk rather than raising more money. It paid a US$10 million cash fee to an institutional investor to irrevocably cancel the investor's right to buy up to US$100 million of additional convertible notes under the October 30, 2025 securities purchase agreement. Those notes could have been amortized at prices tied to ECARX's prevailing share price — with the stock at $0.88, that structure would have converted into a very large number of shares. Removing it caps the potential share issuance and simplifies the capital structure, but the US$10 million fee is real cash leaving the balance sheet, and the company still carries the original US$50 million note plus a convertible program upsized to US$130 million in July 2026 with a US$2.62 conversion price. The trade-off: less future dilution, less cash today.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 32.7% of the 1910 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ECX was trading at $0.88 on NASDAQ in the Technology sector, with a market capitalization of approximately $331.8M. The 52-week trading range was $0.79 to $2.70. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.